- Home
- TEI vs EDIT Comparison
TEI vs EDIT Comparison
Compare TEI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- EDIT
- Stock Information
- Founded
- TEI 1993
- EDIT 2013
- Country
- TEI United States
- EDIT United States
- Employees
- TEI N/A
- EDIT N/A
- Industry
- TEI Finance Companies
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TEI Finance
- EDIT Health Care
- Exchange
- TEI Nasdaq
- EDIT Nasdaq
- Market Cap
- TEI 282.9M
- EDIT 269.8M
- IPO Year
- TEI N/A
- EDIT 2016
- Fundamental
- Price
- TEI $6.43
- EDIT $3.06
- Analyst Decision
- TEI
- EDIT Buy
- Analyst Count
- TEI 0
- EDIT 11
- Target Price
- TEI N/A
- EDIT $4.56
- AVG Volume (30 Days)
- TEI 142.4K
- EDIT 3.0M
- Earning Date
- TEI 01-01-0001
- EDIT 10-31-2025
- Dividend Yield
- TEI 10.51%
- EDIT N/A
- EPS Growth
- TEI N/A
- EDIT N/A
- EPS
- TEI N/A
- EDIT N/A
- Revenue
- TEI N/A
- EDIT $38,901,000.00
- Revenue This Year
- TEI N/A
- EDIT N/A
- Revenue Next Year
- TEI N/A
- EDIT N/A
- P/E Ratio
- TEI N/A
- EDIT N/A
- Revenue Growth
- TEI N/A
- EDIT N/A
- 52 Week Low
- TEI $4.35
- EDIT $0.91
- 52 Week High
- TEI $5.39
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- TEI 64.62
- EDIT 41.49
- Support Level
- TEI $6.45
- EDIT $2.94
- Resistance Level
- TEI $6.28
- EDIT $3.37
- Average True Range (ATR)
- TEI 0.07
- EDIT 0.31
- MACD
- TEI 0.02
- EDIT -0.12
- Stochastic Oscillator
- TEI 87.50
- EDIT 13.01
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.